Evogene (EVGN) Cash from Financing Activities (2013 - 2026)
Evogene (EVGN) posted Cash from Financing Activities of $3.0 million for Q1 2026, up 1269.14% sequentially from -$256000.0 in Q4 2025, and up 1982.39% YoY from $143729.1 in Q1 2025.
Evogene (EVGN) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Evogene has reported Cash from Financing Activities for 14 years, with the latest figure at $3.0 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 1982.39% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.6 million (down 251.31% YoY) and the FY2025 annual result came in at -$6.6 million, down 241.8% from the prior year.
- Cash from Financing Activities climbed to $3.0 million in Q1 2026 per EVGN's latest filing, from -$256000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $10.4 million in Q2 2023 and troughed at -$10.3 million in Q3 2025.
- A 5-year average of $1.4 million and a median of -$100000.0 in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities soared 2931.17% in 2023, then sank 792.45% in 2024.
- Over 5 years, Cash from Financing Activities stood at -$356000.0 in 2022, then surged by 58.71% to -$147000.0 in 2023, then slumped by 40.14% to -$206000.0 in 2024, then fell by 24.27% to -$256000.0 in 2025, then soared by 1269.14% to $3.0 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $3.0 million, -$256000.0, and -$10.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | 2.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.99 Mn |
| Mar 31, 2026 | 2.99 Mn |
| Dec 31, 2025 | -256,000.00 |
| Dec 31, 2025 | -256,000.00 |
| Sep 30, 2025 | -10.34 Mn |
| Sep 30, 2025 | -10.34 Mn |
| Jun 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 3,000.00 |
| Mar 31, 2025 | -159,000.00 |
| Mar 31, 2025 | -159,000.00 |
| Dec 31, 2024 | -206,000.00 |
| Dec 31, 2024 | -206,000.00 |
| Sep 30, 2024 | 5.38 Mn |
| Sep 30, 2024 | 5.38 Mn |
| Jun 30, 2024 | 4,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Mar 31, 2024 | -367,000.00 |
| Mar 31, 2024 | -367,000.00 |
| Dec 31, 2023 | -147,000.00 |
| Dec 31, 2023 | -147,000.00 |